Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119687 | 0.89 | KMT2A (0.50) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119396 | 0.88 | KMT2A (0.49) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119688 | 0.81 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119724 | 0.81 | KMT2A (0.52) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119746 | 0.80 | PDE2A (0.40) | MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL20119392 | 0.79 | CDK1 (0.53) | KMT2ASMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL20119664 | 0.76 | KCNH3 (0.38) | ADORA3ADORA1CHRM4 | |
| SCHEMBL26201937 | 0.75 | KMT2A (0.51) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119378 | 0.75 | KMT2A (0.51) | KMT2ASMN1; SMN2MAPTRECQLKDM4E | |
| SCHEMBL20119934 | 0.75 | HRH4 (0.36) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KMT2A 2971/4885SMN1; SMN2 11/4885MAPT 2133/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KMT2A 2971/4885SMN1; SMN2 11/4885MAPT 2133/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KMT2A 2971/4885SMN1; SMN2 11/4885MAPT 2133/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KMT2A 2971/4885SMN1; SMN2 11/4885MAPT 2133/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KMT2A 2971/4885SMN1; SMN2 11/4885MAPT 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.